Cigna (CI)

• Market cap: $82.1B
• 1 day: 0.04%
• 5 days: 0.23%
• 1 month: 3.89%
• 3 months: -9.17%
• 6 months: -12.44%
• Year to date: 9.22%
• 1 year: -12.69%
• 5 years: 15.22%
• 10 years: 15.22%
• Sector: Financials
• Industry: Hospital & Medical Service Plans

About: Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.

Employees: 72,500

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

13% more call options, than puts

Call options by funds: $1.06B | Put options by funds: $938M

0.19% more ownership

Funds ownership: 86.84% [Q3] → 87.03% (+0.19%) [Q4]

7% less funds holding

Funds holding: 1,670 [Q3] → 1,550 (-120) [Q4]

20% less capital invested

Capital invested by funds: $84B [Q3] → $66.8B (-$17.1B) [Q4]

20% less repeat investments, than reductions

Existing positions increased: 506 | Existing positions reduced: 636

21% less first-time investments, than exits

New positions opened: 162 | Existing positions closed: 206

35% less funds holding in top 10

Funds holding in top 10: 34 [Q3] → 22 (-12) [Q4]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $339 13% upside
• Avg. target: $364 21% upside
• High target: $390 30% upside

10 analyst ratings

• positive: 9 90%
• neutral: 1 10%
• negative: 0 0%

Truist Securities David Macdonald 59% 1-year accuracy 57 / 96 met price target	25% upside $375	Buy Maintained	4 Feb 2025
Wells Fargo Stephen Baxter 24% 1-year accuracy 9 / 38 met price target	14% upside $341	Equal-Weight Maintained	4 Feb 2025
UBS Kevin Caliendo 50% 1-year accuracy 8 / 16 met price target	30% upside $390	Buy Maintained	3 Feb 2025
Piper Sandler Jessica Tassan 35% 1-year accuracy 8 / 23 met price target	16% upside $348	Overweight Reiterated	3 Feb 2025
Oppenheimer Michael Wiederhorn 31% 1-year accuracy 10 / 32 met price target	25% upside $375	Outperform Maintained	31 Jan 2025